Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255933 | 0.85 | CRHR1 (0.33) | ALDH1A1KMT2ACRHR1 | |
| SCHEMBL2260071 | 0.74 | CRHR1 (0.36) | ALDH1A1LMNAKDM4ECRHR1DPP4 | |
| SCHEMBL12360843 | 0.69 | DPP4 (0.41) | CRHR1DPP4DPP8DPP9 | |
| SCHEMBL13494254 | 0.69 | CRHR1 (0.41) | CRHR1DPP4DPP8DPP9 | |
| SCHEMBL2254964 | 0.66 | CRHR1 (0.34) | CRHR1 | |
| SCHEMBL1922951 | 0.65 | CRHR1 (0.50) | CRHR1DPP4 | |
| SCHEMBL1922576 | 0.64 | CRHR1 (0.38) | CRHR1DPP4 | |
| SCHEMBL2256732 | 0.64 | CRHR1 (0.39) | CRHR1DPP4DPP8DPP9 | |
| SCHEMBL1922585 | 0.64 | DPP4 (0.44) | CRHR1DPP4DPP8DPP9 | |
| SCHEMBL2256841 | 0.62 | CRHR1 (0.38) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035874-A1 | Organic compounds | CRH, CRHR1, CRHR2 | ALDH1A1 1728/4885LMNA 4856/4885KDM4E 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.